Sign in

    Alexandria Real Estate Equities Inc (ARE)

    You might also like

    Business Description

    Alexandria Real Estate Equities, Inc. (ARE) is a Maryland-based Real Estate Investment Trust (REIT) specializing in the life science, agtech, and advanced technology sectors. The company is renowned for owning, operating, and developing collaborative life science mega campuses in major innovation hubs such as Greater Boston, San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle . ARE's portfolio includes Class A/A+ properties that foster dynamic and collaborative environments for tenants, which consist of multinational pharmaceutical companies, biotechnology firms, and academic institutions . The company's revenue is primarily generated from rental payments and operating expense reimbursements under leases, with a significant portion of tenants being investment-grade or publicly traded large cap companies . Additionally, ARE diversifies its revenue through venture capital investments in transformative life science companies .

    1. Real Estate Operations - Owns, operates, and develops Class A/A+ life science mega campuses in key innovation clusters, providing dynamic environments for tenants.
    2. Leasing - Generates revenue from rental payments and operating expense reimbursements, with a focus on investment-grade or publicly traded large cap tenants.
    3. Venture Capital Investments - Engages in investments in transformative life science companies to diversify revenue streams.

    Key Metrics

    View all financials →

    Executive Team

    NamePositionStart DateShort Bio
    Joel S. MarcusExecutive Chairman and Founder1994Joel S. Marcus co-founded Alexandria Real Estate Equities, Inc. in 1994 as a garage startup with $19 million in Series A capital. Under his leadership, Alexandria has grown into a leading S&P 500 company focused on life science mega campuses in key innovation cluster locations .
    Peter M. MogliaChief Executive Officer and Chief Investment OfficerJuly 2022Peter M. Moglia has been serving as the Chief Executive Officer since July 2022 and as the Chief Investment Officer since September 2023. He has been with the company since April 1998 .
    Daniel J. RyanCo-President and Regional Market Director – San DiegoSeptember 2023Daniel J. Ryan has been with Alexandria since June 2010. He has served as Co-President and Regional Market Director – San Diego since September 2023 .
    Hunter L. KassCo-President and Regional Market Director – Greater BostonSeptember 2023Hunter L. Kass has been with Alexandria since 2018. He currently serves as Co-President and Regional Market Director for Greater Boston, a position he has held since September 2023 .
    Marc E. BindaChief Financial Officer and TreasurerSeptember 2023Marc E. Binda has served as the Chief Financial Officer since September 2023 and as Treasurer since April 2018. He joined the company in January 2005 .
    Vincent R. CiruzziChief Development OfficerOctober 2015Vincent R. Ciruzzi has served as the Chief Development Officer since October 2015. He joined the company as Vice President in September 1996 .
    Lawrence J. DiamondCo-Chief Operating Officer and Regional Market Director – MarylandApril 2018Lawrence J. Diamond has served as Co-Chief Operating Officer since April 2018 and as Regional Market Director – Maryland since July 2005 .
    Joseph HakmanCo-Chief Operating Officer and Chief Strategic Transactions OfficerJuly 2020Joseph Hakman has served as Co-Chief Operating Officer since July 2020 and as Chief Strategic Transactions Officer since June 2019 .
    John Hart ColeExecutive Vice President – Capital Markets/Strategic Operations and Co-Regional Market Director – SeattleJanuary 2024John Hart Cole has served in his current roles since January 2024. He was previously the Senior Vice President – Strategic Market Director – Seattle from October 2017 to December 2023 .
    Jackie B. ClemGeneral Counsel and SecretaryJuly 2020Jackie B. Clem has served as General Counsel and Secretary since July 2020. She has been with the company since 2006 .
    Gary D. DeanExecutive Vice President – Real Estate Legal AffairsJuly 2020Gary D. Dean has served as Executive Vice President – Real Estate Legal Affairs since July 2020. He joined the company in 2004 .
    Andres R. GavinetChief Accounting OfficerJune 2012Andres R. Gavinet has served as the Chief Accounting Officer since June 2012. He oversees the company's accounting and financial reporting functions .
    Orraparn C. LeeExecutive Vice President – AccountingMarch 2022Orraparn C. Lee has served as Executive Vice President – Accounting since March 2022. She has been with the company since October 2009 .
    Kristina A. Fukuzaki-CarlsonExecutive Vice President – Business OperationsMarch 2022Kristina A. Fukuzaki-Carlson has served as Executive Vice President – Business Operations since March 2022. She joined the company in October 2005 .
    Madeleine T. AlsbrookExecutive Vice President – Talent ManagementMarch 2022Madeleine T. Alsbrook has served as Executive Vice President – Talent Management since March 2022. She joined the company in 2012 .

    Questions to Ask Management

    1. Given that tenants are transitioning to a "just-in-time" model for space and leasing cycles are taking longer due to increased Board scrutiny , how do you plan to maintain occupancy levels and lease growth in this more conservative environment?

    2. With high cost of capital and increasing financing costs impacting your ability to fund new developments , how are you evaluating the trade-offs between asset sales to fund construction and maintaining future growth opportunities?

    3. Considering that companies without clear catalysts are struggling to access additional capital, affecting pre-commercial public biotech companies which constitute 9% of your ARR , how does this impact your tenant base and what strategies are you employing to mitigate potential occupancy risks?

    4. As sublease space in key markets like Boston and the Bay Area remains available despite stabilization , how are you addressing the competition from sublease space, and what impact do you anticipate this will have on your leasing activities and rental rates?

    5. With AI advancements potentially optimizing drug discovery and clinical trials, possibly reducing the need for physical lab space , how are you positioning Alexandria to adapt to these technological changes and ensure sustained demand for your lab facilities?

    Debt Maturity Schedule

    YearAmount Due (in billions)Debt TypeInterest Rate% of Total Debt
    20250.600Unsecured Senior Notes Payable3.45% 4.9% = (0.600 / 12.244) * 100
    20250.600Unconsolidated Joint Venture Debt4.57% 4.9% = (0.600 / 12.244) * 100
    20260.800Secured Notes Payable4.30% 6.5% = (0.800 / 12.244) * 100
    20260.800Unsecured Senior Notes Payable3.80% 6.5% = (0.800 / 12.244) * 100
    20270.350Unsecured Senior Notes Payable3.95% 2.9% = (0.350 / 12.244) * 100
    20280.425Unsecured Senior Notes Payable3.95% 3.5% = (0.425 / 12.244) * 100
    20290.700Unsecured Senior Notes Payable4.50% 5.7% = (0.700 / 12.244) * 100
    20301.150Unsecured Senior Notes Payable4.70% 9.4% = (1.150 / 12.244) * 100
    20310.750Unsecured Senior Notes Payable3.375% 6.1% = (0.750 / 12.244) * 100
    20320.900Unsecured Senior Notes Payable2.00% 7.4% = (0.900 / 12.244) * 100
    20331.000Unsecured Senior Notes Payable1.875% 8.2% = (1.000 / 12.244) * 100
    20340.800Unsecured Senior Notes Payable2.95% 6.5% = (0.800 / 12.244) * 100
    20350.500Unsecured Senior Notes Payable4.75% 4.1% = (0.500 / 12.244) * 100
    20360.400Unsecured Senior Notes Payable5.25% 3.3% = (0.400 / 12.244) * 100
    20490.300Unsecured Senior Notes Payable4.85% 2.4% = (0.300 / 12.244) * 100
    20500.700Unsecured Senior Notes Payable4.00% 5.7% = (0.700 / 12.244) * 100
    20510.850Unsecured Senior Notes Payable3.00% 6.9% = (0.850 / 12.244) * 100
    20521.000Unsecured Senior Notes Payable3.55% 8.2% = (1.000 / 12.244) * 100
    20530.500Unsecured Senior Notes Payable5.15% 4.1% = (0.500 / 12.244) * 100
    20540.600Unsecured Senior Notes Payable5.625% 4.9% = (0.600 / 12.244) * 100

    Customer Concentration

    CustomerRelationshipSegmentDetails
    Eli Lilly and Company
    Leases from ARE
    All
    4.3% of total annual rental revenue, \$90.3M.
    Moderna, Inc.
    Leases from ARE
    All
    4.3% of total annual rental revenue, \$90.1M.
    Bristol-Myers Squibb Company
    Leases from ARE
    All
    3.7% of total annual rental revenue, \$77.2M.
    Takeda Pharmaceutical Company
    Leases from ARE
    All
    2.3% of total annual rental revenue, \$47.9M.
    Roche
    Leases from ARE
    All
    1.8% of total annual rental revenue, \$37.4M.
    Illumina, Inc.
    Leases from ARE
    All
    1.7% of total annual rental revenue, \$35.9M.
    Alphabet Inc.
    Leases from ARE
    All
    1.7% of total annual rental revenue, \$34.9M.
    2seventy bio, Inc.
    Leases from ARE
    All
    1.6% of total annual rental revenue, \$33.5M.
    United States Government
    Leases from ARE
    All
    1.4% of total annual rental revenue, \$28.9M.
    Cloud Software Group, Inc.
    Leases from ARE
    All
    1.4% of total annual rental revenue, \$28.5M.
    Novartis AG
    Leases from ARE
    All
    1.3% of total annual rental revenue, \$28.0M.
    Uber Technologies, Inc.
    Leases from ARE
    All
    1.3% of total annual rental revenue, \$27.8M.
    AstraZeneca PLC
    Leases from ARE
    All
    1.3% of total annual rental revenue, \$27.2M.
    Boston Children’s Hospital
    Leases from ARE
    All
    1.2% of total annual rental revenue, \$26.2M.
    The Regents of the University of California
    Leases from ARE
    All
    1.1% of total annual rental revenue, \$23.5M.
    Sanofi
    Leases from ARE
    All
    1.0% of total annual rental revenue, \$21.4M.
    Merck & Co., Inc.
    Leases from ARE
    All
    1.0% of total annual rental revenue, \$21.4M.
    New York University
    Leases from ARE
    All
    1.0% of total annual rental revenue, \$21.1M.
    Charles River Laboratories, Inc.
    Leases from ARE
    All
    1.0% of total annual rental revenue, \$20.6M.
    Massachusetts Institute of Technology
    Leases from ARE
    All
    1.0% of total annual rental revenue, \$20.2M.

    Auditor

    NameStart DateEnd DateReason for Change
    Ernst & Young LLP1994 PresentCurrent auditor

    Latest news

    Recent developments and announcements about ARE.

    Financial Reporting

      Earnings Call

      ·
      8 days ago

      The document set does not contain a specific earnings call transcript release for ARE, but it does include detailed discussions from their recent earnings call. Below is a summary of key points:

      Revenue and Profit Performance

      • Revenue and EBITDA Growth: Total revenues and adjusted EBITDA for 2024 increased by 8% and 11.6%, respectively, compared to 2023. This growth was driven by strong same-property performance and development execution.
      • FFO Growth: Funds from Operations (FFO) per share as adjusted was $9.47, reflecting a 5.6% increase over 2023 and a 36% increase over the last three years.

      Management’s Forward Guidance

      • Leasing Momentum: Leasing volume for 2024 was 5.1 million square feet, up 17% from the prior year. The company expects strong leasing activity to continue into 2025, with 90% of the 2025 pipeline already leased or under signed Letters of Intent (LOIs).
      • Development Pipeline: The company is focused on its redevelopment and development pipeline, with significant progress expected in 2025 and 2026. However, leasing for 2027 and beyond remains a work in progress.
      • Capital Allocation: ARE has completed $1.1 billion in capital recycling and plans to focus on mega campuses while exiting non-core assets.

      Market Conditions and Strategic Initiatives

      • Sector Diversification: While biotech leasing has slowed due to macroeconomic conditions, other sectors, including AI and institutional tenants, have shown strong demand. The company remains optimistic about the biotech sector rebounding as interest rates stabilize.
      • Cost Savings: ARE achieved significant G&A savings in 2024 and expects further reductions in 2025, with a projected $30+ million decline in expenses.
      • Insurance and Risk Management: The company has taken steps to mitigate risks related to natural disasters, particularly in California, and maintains strong insurance coverage.

      Analyst Questions and Management Responses

      • Buybacks: ARE has already executed $150 million in buybacks for 2025 and will continue to evaluate further buybacks based on market conditions.
      • Leasing Economics: Tenant improvement (TI) costs and leasing commissions have stabilized, and the company is adjusting its economics to align with market conditions.
      • Funding Environment: Venture capital funding for biotech has decreased from 2021 peaks but remains strong, with significant dry powder available for deployment in 2025.

      Key Analyst Topics

      • Leasing Velocity: Analysts emphasized the importance of leasing velocity for ARE’s growth. Management highlighted that most leasing activity comes from existing tenants and that the biotech sector’s recovery depends on macroeconomic factors, including interest rate reductions.
      • Development Spending: The majority of development spending is allocated to active projects, with limited new projects expected to start in the near term.

      This summary captures the main points discussed during ARE’s earnings call, including financial performance, forward guidance, and strategic initiatives. If you need further details or specific sections of the transcript, please let me know.

      Earnings Report

      ·
      Jan 27, 2025, 9:34 PM

      Alexandria Real Estate Equities, Inc. (ARE) Earnings Results for Q4 and Full Year 2024

      Alexandria Real Estate Equities, Inc. has released its financial and operating results for the fourth quarter and year ended December 31, 2024. Below are the key highlights:

      Financial Performance

      • Total Revenues: $788.9 million for Q4 2024, reflecting a 4.2% increase compared to Q4 2023. For the full year, revenues reached $3.12 billion, an 8.0% growth year-over-year.
      • Net Income: A net loss of $(64.9) million for Q4 2024, translating to $(0.38) per share. For the full year, net income was $309.6 million, or $1.80 per share.
      • Funds From Operations (FFO): Adjusted FFO per share was $2.39 for Q4 2024 and $9.47 for the full year, showing strong operational performance.

      Operational Metrics

      • Occupancy: Operating properties in North America maintained a high occupancy rate of 94.6% as of December 31, 2024.
      • Top Tenants: 92% of annual rental revenue from the top 20 tenants is derived from investment-grade or publicly traded large-cap tenants.
      • Adjusted EBITDA Margin: The margin stood at 72% for Q4 2024, consistent with prior quarters.

      Key Trends and Highlights

      • Same Property Performance: Net operating income (NOI) for same properties increased by 0.6% in Q4 2024 and 1.2% for the full year. On a cash basis, NOI grew by 6.3% in Q4 and 4.6% for the year.
      • Leasing Activity: Rental rate changes for lease renewals and re-leasing of space showed an 18.1% increase in Q4 2024, with a cash basis increase of 3.3%.
      • Dividend: A quarterly dividend of $1.32 per share was declared, representing an annualized yield of 5.4%.

      Capital Events

      • Stock Repurchase Program: As of January 27, 2025, ARE repurchased $200.1 million worth of common stock under its $500 million repurchase program, with an average price of $98.16 per share.
      • Debt Metrics: Net debt to Adjusted EBITDA ratio was 5.2x, reflecting a strong and flexible balance sheet.

      Upcoming Events

      • Earnings Call: A conference call is scheduled for January 28, 2025, at 3:00 PM ET to discuss these results. Details for participation are available on the company’s website.

      For further details, the full earnings press release and supplemental information can be accessed on ARE's website.

      Sources: , , , , , , , , , , ,

    Corporate Leadership

      Leadership Change

      ·
      Dec 9, 2024, 2:18 PM

      Vincent R. Ciruzzi, Chief Development Officer of Alexandria Real Estate Equities, Inc., is resigning effective December 31, 2024, after nearly 30 years of service. The company has not announced a successor yet .